Coordinatore | KAROLINSKA INSTITUTET
Organization address
address: Nobels Vag 5 contact info |
Nazionalità Coordinatore | Sweden [SE] |
Sito del progetto | http://www.fp7infect.eu |
Totale costo | 15˙678˙988 € |
EC contributo | 11˙913˙591 € |
Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
Code Call | FP7-HEALTH-2012-INNOVATION-1 |
Funding Scheme | CP-IP |
Anno di inizio | 2013 |
Periodo (anno-mese-giorno) | 2013-01-01 - 2017-12-31 |
# | ||||
---|---|---|---|---|
1 |
KAROLINSKA INSTITUTET
Organization address
address: Nobels Vag 5 contact info |
SE (STOCKHOLM) | coordinator | 2˙110˙979.00 |
2 |
HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH
Organization address
address: Inhoffenstrasse 7 contact info |
DE (BRAUNSCHWEIG) | participant | 1˙702˙400.00 |
3 |
UNIVERSITY OF NORTH DAKOTA
Organization address
address: CENTENNIAL DRIVE 264 STOP 8356 TWAMLEY HALL ROOM 115 contact info |
US (GRAND FORKS ND) | participant | 1˙423˙730.20 |
4 |
WAGENINGEN UNIVERSITY
Organization address
address: DROEVENDAALSESTEEG 4 contact info |
NL (WAGENINGEN) | participant | 1˙324˙548.00 |
5 |
REGION HOVEDSTADEN
Organization address
address: KONGENS VAENGE 2 contact info |
DK (HILLEROD) | participant | 1˙062˙774.00 |
6 |
UNIVERSITETET I BERGEN
Organization address
address: Museplassen 1 contact info |
NO (BERGEN) | participant | 886˙513.00 |
7 |
LIFEGLIMMER GMBH
Organization address
address: MARKELSTRASSE 39 A contact info |
DE (BERLIN) | participant | 610˙354.00 |
8 |
STOCKHOLMS LAENS LANDSTING
Organization address
address: Hantverkargatan 45 contact info |
SE (STOCKHOLM) | participant | 605˙095.00 |
9 |
ANAGNOSTICS BIOANALYSIS GMBH
Organization address
address: WESTBAHNSTRASSE 55 contact info |
AT (ST VALENTIN) | participant | 482˙020.00 |
10 |
VASTRA GOTALANDS LANS LANDSTING
Organization address
address: REGIONENS HUS contact info |
SE (VANERSBORG) | participant | 435˙000.00 |
11 |
BLEKINGE LANS LANDSTING
Organization address
city: KARLSKRONA contact info |
SE (KARLSKRONA) | participant | 390˙197.00 |
12 |
TEL AVIV UNIVERSITY
Organization address
address: RAMAT AVIV contact info |
IL (TEL AVIV) | participant | 382˙000.00 |
13 |
UNIVERSITE LYON 1 CLAUDE BERNARD
Organization address
address: BOULEVARD DU 11 NOVEMBRE 1918 NUM43 contact info |
FR (VILLEURBANNE CEDEX) | participant | 356˙799.00 |
14 |
University of Cincinnati
Organization address
address: "Cincinnati,Ohio" contact info |
US (Cincinnati) | participant | 93˙736.75 |
15 |
MARSDEN DOREEN
Organization address
address: MOOR HEY FARM KNOWLE GREEN contact info |
UK (PRESTON) | participant | 47˙445.00 |
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
'The overall goal with INFECT is to advance our understanding of the pathophysiological mechanisms, prognosis, and diagnosis of the multifactorial highly lethal NSTIs. The fulminant course of NSTIs (in the order of hours) demands immediate diagnosis and adequate interventions in order to salvage lives and limbs. However, diagnosis and management are difficult due to heterogeneity in clinical presentation, in co-morbidities and in microbiological aetiology. Thus, there is an urgent need for novel diagnostic and therapeutic strategies in order to improve outcome of NSTIs. To achieve this, a comprehensive and integrated knowledge of diagnostic features, causative microbial agent, treatment strategies, and pathogenic mechanisms (host and bacterial disease traits and their underlying interaction network) is required. INFECT is designed to obtain such insights through an integrated systems biology approach in patients and different clinically relevant experimental models.
Specific objectives of INFECT are to: 1. Unravel specific mechanisms underlying diseases signatures though a bottom-up systems approach applied to clinically relevant experimental settings 2. Apply a top-down systems biology approach to NSTI patient samples to pin-point key host and pathogen factors involved in the onset and development of infection 3. Identify and quantify disease signatures and underlying networks that contribute to disease outcome 4. Exploit identified disease traits for the innovation of optimized diagnostic tools 5. Translate the advanced knowledge generated into evidence-based guidelines for classification and management, and novel therapeutic strategies
We have gathered a team of multidisciplinary researchers, clinicians, SMEs and a patient organization, each with a unique expertise, technical platform and/or model systems that together provide the means to successfully conduct the multifaceted research proposed and efficiently disseminate/exploit the knowledge obtained.'
Key Performance Factor Assessment and Valorisation for Successful EU-FP Project Participation of innovative SMEs in the Area of HEALTH
Read More